| Biological Sciences | Lifetime | 155 | CH 2 | 99.98 |
| Biological Sciences | 2021-2025 | 582 | CH 3 | 99.38 |
| Molecular Medicine | Lifetime | 2 | CH 2 | 99.94 |
| Endocrinology | Lifetime | 15 | CH 2 | 99.77 |
| Clinical Pharmacology | Lifetime | 263 | CH 4 | 98.93 |
| Pollution | Lifetime | 193 | CH 5 | 98.88 |
| Clinical Biochemistry | Lifetime | 504 | CH 12 | 90.49 |
| Molecular Medicine | 2021-2025 | 13 | CH 1 | 98.91 |
| Clinical Pharmacology | 2021-2025 | 168 | CH 2 | 94.09 |
| Endocrinology | 2021-2025 | 54 | CH 6 | 89.46 |
| Antibiotic Resistance in Bacteria | Lifetime | 2 | CH 2 | 99.98 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 4 | CH 2 | 99.96 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 7 | CH 2 | 99.95 |
| Bacterial biofilms and quorum sensing | Lifetime | 8 | CH 2 | 99.92 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 2 | CH 2 | 99.94 |
| Vibrio bacteria research studies | Lifetime | 7 | CH 2 | 99.92 |
| Infections and bacterial resistance | Lifetime | 2 | CH 2 | 99.93 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 107 | CH 6 | 99.35 |
| Antibiotic Use and Resistance | Lifetime | 105 | CH 5 | 99.22 |
| Tuberculosis Research and Epidemiology | Lifetime | 287 | CH 9 | 98.89 |
| Escherichia coli research studies | Lifetime | 133 | CH 2 | 98.66 |
| Plant Pathogenic Bacteria Studies | Lifetime | 154 | CH 8 | 98.44 |
| Bacterial Genetics and Biotechnology | Lifetime | 339 | CH 6 | 98.61 |
| Pneumonia and Respiratory Infections | Lifetime | 541 | CH 11 | 98.18 |
| Mycobacterium research and diagnosis | Lifetime | 748 | CH 20 | 96.79 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 534 | CH 14 | 97.38 |
| Salmonella and Campylobacter epidemiology | Lifetime | 631 | CH 11 | 96.62 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 904 | CH 24 | 96.40 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 275 | CH 5 | 84.40 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 36 | CH 1 | 99.30 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 25 | CH 2 | 98.94 |
| Pharmaceutical and Antibiotic Environmental Impacts | 2021-2025 | 117 | CH 1 | 97.61 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 14 | CH 2 | 95.18 |
| Antibiotic Use and Resistance | 2021-2025 | 247 | CH 9 | 94.74 |
| Pneumonia and Respiratory Infections | 2021-2025 | 398 | CH 11 | 92.73 |
| Vibrio bacteria research studies | 2021-2025 | 204 | CH 6 | 90.24 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 430 | CH 11 | 88.28 |
| Bacterial biofilms and quorum sensing | 2021-2025 | 802 | CH 17 | 81.92 |
| Escherichia coli research studies | 2021-2025 | 306 | CH 7 | 81.41 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 722 | CH 22 | 80.69 |
| Infections and bacterial resistance | 2021-2025 | 93 | CH 1 | 77.38 |
